Global Neisseria meningitidis Infections Drug market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031. Get Access Now!

Global Neisseria meningitidis Infections Drug Market Size and Outlook 2025-31

The global Neisseria meningitidis Infections Drug market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031. The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs. Infinity Market Research newest research report, the Neisseria meningitidis Infections Drug Industry Forecast looks at past sales and reviews total world Neisseria meningitidis Infections Drug sales in 2024, providing a comprehensive analysis by region and market sector of projected Neisseria meningitidis Infections Drug sales for 2025 through 2031. With Neisseria meningitidis Infections Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Neisseria meningitidis Infections Drug industry. This Insight Report provides a comprehensive analysis of the global Neisseria meningitidis Infections Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Neisseria meningitidis Infections Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms unique position in an accelerating global Neisseria meningitidis Infections Drug market. This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Neisseria meningitidis Infections Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Neisseria meningitidis Infections Drug. This report presents a comprehensive overview, market shares, and growth opportunities of Neisseria meningitidis Infections Drug market by product type, application, key manufacturers and key regions and countries. Segmentation by Type: &nbsp;&nbsp;&nbsp; MGBBP-3 &nbsp;&nbsp;&nbsp; NCL-195 &nbsp;&nbsp;&nbsp; TP-10 &nbsp;&nbsp;&nbsp; Others Segmentation by Application: &nbsp;&nbsp;&nbsp; Hospital &nbsp;&nbsp;&nbsp; Clinic &nbsp;&nbsp;&nbsp; Others This report also splits the market by region: &nbsp;&nbsp;&nbsp; Americas &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; United States &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Canada &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mexico &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Brazil &nbsp;&nbsp;&nbsp; APAC &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; China &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Japan &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Korea &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Southeast Asia &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; India &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Australia &nbsp;&nbsp;&nbsp; Europe &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Germany &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; France &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; UK &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Italy &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Russia &nbsp;&nbsp;&nbsp; Middle East & Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Egypt &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; South Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Israel &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Turkey &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; GCC Countries The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the companys coverage, product portfolio, its market penetration. &nbsp;&nbsp;&nbsp; Beijing Minhai Biotechnology Co Ltd &nbsp;&nbsp;&nbsp; Biological E Ltd &nbsp;&nbsp;&nbsp; China National Pharmaceutical Group Corp &nbsp;&nbsp;&nbsp; GlaxoSmithKline Plc &nbsp;&nbsp;&nbsp; Griffith University &nbsp;&nbsp;&nbsp; ImmunoBiology Ltd &nbsp;&nbsp;&nbsp; JN-International Medical Corp &nbsp;&nbsp;&nbsp; MGB Biopharma Ltd &nbsp;&nbsp;&nbsp; Panacea Biotec Ltd &nbsp;&nbsp;&nbsp; Pfizer Inc &nbsp;&nbsp;&nbsp; Sanofi Pasteur SA &nbsp;&nbsp;&nbsp; Serum Institute of India Ltd &nbsp;&nbsp;&nbsp; Wellstat Vaccines LLC Key Questions Addressed in this Report What is the 10-year outlook for the global Neisseria meningitidis Infections Drug market? What factors are driving Neisseria meningitidis Infections Drug market growth, globally and by region? Which technologies are poised for the fastest growth by market and region? How do Neisseria meningitidis Infections Drug market opportunities vary by end market size? How does Neisseria meningitidis Infections Drug break out by Type, by Application?

1 Scope of the Report &nbsp;1.1 Market Introduction &nbsp;1.2 Years Considered &nbsp;1.3 Research Objectives &nbsp;1.4 Market Research Methodology &nbsp;1.5 Research Process and Data Source &nbsp;1.6 Economic Indicators &nbsp;1.7 Currency Considered &nbsp;1.8 Market Estimation Caveats 2 Executive Summary &nbsp;2.1 World Market Overview &nbsp;2.1.1 Global Neisseria meningitidis Infections Drug Annual Sales 2020-2031 &nbsp;2.1.2 World Current & Future Analysis for Neisseria meningitidis Infections Drug by Geographic Region, 2020, 2024 & 2031 &nbsp;2.1.3 World Current & Future Analysis for Neisseria meningitidis Infections Drug by Country/Region, 2020, 2024 & 2031 &nbsp;2.2 Neisseria meningitidis Infections Drug Segment by Type &nbsp;2.2.1 MGBBP-3 &nbsp;2.2.2 NCL-195 &nbsp;2.2.3 TP-10 &nbsp;2.2.4 Others &nbsp;2.3 Neisseria meningitidis Infections Drug Sales by Type &nbsp;2.3.1 Global Neisseria meningitidis Infections Drug Sales Market Share by Type (2020-2025) &nbsp;2.3.2 Global Neisseria meningitidis Infections Drug Revenue and Market Share by Type (2020-2025) &nbsp;2.3.3 Global Neisseria meningitidis Infections Drug Sale Price by Type (2020-2025) &nbsp;2.4 Neisseria meningitidis Infections Drug Segment by Application &nbsp;2.4.1 Hospital &nbsp;2.4.2 Clinic &nbsp;2.4.3 Others &nbsp;2.5 Neisseria meningitidis Infections Drug Sales by Application &nbsp;2.5.1 Global Neisseria meningitidis Infections Drug Sale Market Share by Application (2020-2025) &nbsp;2.5.2 Global Neisseria meningitidis Infections Drug Revenue and Market Share by Application (2020-2025) &nbsp;2.5.3 Global Neisseria meningitidis Infections Drug Sale Price by Application (2020-2025) 3 Global by Company &nbsp;3.1 Global Neisseria meningitidis Infections Drug Breakdown Data by Company &nbsp;3.1.1 Global Neisseria meningitidis Infections Drug Annual Sales by Company (2020-2025) &nbsp;3.1.2 Global Neisseria meningitidis Infections Drug Sales Market Share by Company (2020-2025) &nbsp;3.2 Global Neisseria meningitidis Infections Drug Annual Revenue by Company (2020-2025) &nbsp;3.2.1 Global Neisseria meningitidis Infections Drug Revenue by Company (2020-2025) &nbsp;3.2.2 Global Neisseria meningitidis Infections Drug Revenue Market Share by Company (2020-2025) &nbsp;3.3 Global Neisseria meningitidis Infections Drug Sale Price by Company &nbsp;3.4 Key Manufacturers Neisseria meningitidis Infections Drug Producing Area Distribution, Sales Area, Product Type &nbsp;3.4.1 Key Manufacturers Neisseria meningitidis Infections Drug Product Location Distribution &nbsp;3.4.2 Players Neisseria meningitidis Infections Drug Products Offered &nbsp;3.5 Market Concentration Rate Analysis &nbsp;3.5.1 Competition Landscape Analysis &nbsp;3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025) &nbsp;3.6 New Products and Potential Entrants &nbsp;3.7 Market M&A Activity & Strategy 4 World Historic Review for Neisseria meningitidis Infections Drug by Geographic Region &nbsp;4.1 World Historic Neisseria meningitidis Infections Drug Market Size by Geographic Region (2020-2025) &nbsp;4.1.1 Global Neisseria meningitidis Infections Drug Annual Sales by Geographic Region (2020-2025) &nbsp;4.1.2 Global Neisseria meningitidis Infections Drug Annual Revenue by Geographic Region (2020-2025) &nbsp;4.2 World Historic Neisseria meningitidis Infections Drug Market Size by Country/Region (2020-2025) &nbsp;4.2.1 Global Neisseria meningitidis Infections Drug Annual Sales by Country/Region (2020-2025) &nbsp;4.2.2 Global Neisseria meningitidis Infections Drug Annual Revenue by Country/Region (2020-2025) &nbsp;4.3 Americas Neisseria meningitidis Infections Drug Sales Growth &nbsp;4.4 APAC Neisseria meningitidis Infections Drug Sales Growth &nbsp;4.5 Europe Neisseria meningitidis Infections Drug Sales Growth &nbsp;4.6 Middle East & Africa Neisseria meningitidis Infections Drug Sales Growth 5 Americas &nbsp;5.1 Americas Neisseria meningitidis Infections Drug Sales by Country &nbsp;5.1.1 Americas Neisseria meningitidis Infections Drug Sales by Country (2020-2025) &nbsp;5.1.2 Americas Neisseria meningitidis Infections Drug Revenue by Country (2020-2025) &nbsp;5.2 Americas Neisseria meningitidis Infections Drug Sales by Type (2020-2025) &nbsp;5.3 Americas Neisseria meningitidis Infections Drug Sales by Application (2020-2025) &nbsp;5.4 United States &nbsp;5.5 Canada &nbsp;5.6 Mexico &nbsp;5.7 Brazil 6 APAC &nbsp;6.1 APAC Neisseria meningitidis Infections Drug Sales by Region &nbsp;6.1.1 APAC Neisseria meningitidis Infections Drug Sales by Region (2020-2025) &nbsp;6.1.2 APAC Neisseria meningitidis Infections Drug Revenue by Region (2020-2025) &nbsp;6.2 APAC Neisseria meningitidis Infections Drug Sales by Type (2020-2025) &nbsp;6.3 APAC Neisseria meningitidis Infections Drug Sales by Application (2020-2025) &nbsp;6.4 China &nbsp;6.5 Japan &nbsp;6.6 South Korea &nbsp;6.7 Southeast Asia &nbsp;6.8 India &nbsp;6.9 Australia &nbsp;6.10 China Taiwan 7 Europe &nbsp;7.1 Europe Neisseria meningitidis Infections Drug by Country &nbsp;7.1.1 Europe Neisseria meningitidis Infections Drug Sales by Country (2020-2025) &nbsp;7.1.2 Europe Neisseria meningitidis Infections Drug Revenue by Country (2020-2025) &nbsp;7.2 Europe Neisseria meningitidis Infections Drug Sales by Type (2020-2025) &nbsp;7.3 Europe Neisseria meningitidis Infections Drug Sales by Application (2020-2025) &nbsp;7.4 Germany &nbsp;7.5 France &nbsp;7.6 UK &nbsp;7.7 Italy &nbsp;7.8 Russia 8 Middle East & Africa &nbsp;8.1 Middle East & Africa Neisseria meningitidis Infections Drug by Country &nbsp;8.1.1 Middle East & Africa Neisseria meningitidis Infections Drug Sales by Country (2020-2025) &nbsp;8.1.2 Middle East & Africa Neisseria meningitidis Infections Drug Revenue by Country (2020-2025) &nbsp;8.2 Middle East & Africa Neisseria meningitidis Infections Drug Sales by Type (2020-2025) &nbsp;8.3 Middle East & Africa Neisseria meningitidis Infections Drug Sales by Application (2020-2025) &nbsp;8.4 Egypt &nbsp;8.5 South Africa &nbsp;8.6 Israel &nbsp;8.7 Turkey &nbsp;8.8 GCC Countries 9 Market Drivers, Challenges and Trends &nbsp;9.1 Market Drivers & Growth Opportunities &nbsp;9.2 Market Challenges & Risks &nbsp;9.3 Industry Trends 10 Manufacturing Cost Structure Analysis &nbsp;10.1 Raw Material and Suppliers &nbsp;10.2 Manufacturing Cost Structure Analysis of Neisseria meningitidis Infections Drug &nbsp;10.3 Manufacturing Process Analysis of Neisseria meningitidis Infections Drug &nbsp;10.4 Industry Chain Structure of Neisseria meningitidis Infections Drug 11 Marketing, Distributors and Customer &nbsp;11.1 Sales Channel &nbsp;11.1.1 Direct Channels &nbsp;11.1.2 Indirect Channels &nbsp;11.2 Neisseria meningitidis Infections Drug Distributors &nbsp;11.3 Neisseria meningitidis Infections Drug Customer 12 World Forecast Review for Neisseria meningitidis Infections Drug by Geographic Region &nbsp;12.1 Global Neisseria meningitidis Infections Drug Market Size Forecast by Region &nbsp;12.1.1 Global Neisseria meningitidis Infections Drug Forecast by Region (2026-2031) &nbsp;12.1.2 Global Neisseria meningitidis Infections Drug Annual Revenue Forecast by Region (2026-2031) &nbsp;12.2 Americas Forecast by Country (2026-2031) &nbsp;12.3 APAC Forecast by Region (2026-2031) &nbsp;12.4 Europe Forecast by Country (2026-2031) &nbsp;12.5 Middle East & Africa Forecast by Country (2026-2031) &nbsp;12.6 Global Neisseria meningitidis Infections Drug Forecast by Type (2026-2031) &nbsp;12.7 Global Neisseria meningitidis Infections Drug Forecast by Application (2026-2031) 13 Key Players Analysis &nbsp;13.1 Beijing Minhai Biotechnology Co Ltd &nbsp;13.1.1 Beijing Minhai Biotechnology Co Ltd Company Information &nbsp;13.1.2 Beijing Minhai Biotechnology Co Ltd Neisseria meningitidis Infections Drug Product Portfolios and Specifications &nbsp;13.1.3 Beijing Minhai Biotechnology Co Ltd Neisseria meningitidis Infections Drug Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.1.4 Beijing Minhai Biotechnology Co Ltd Main Business Overview &nbsp;13.1.5 Beijing Minhai Biotechnology Co Ltd Latest Developments &nbsp;13.2 Biological E Ltd &nbsp;13.2.1 Biological E Ltd Company Information &nbsp;13.2.2 Biological E Ltd Neisseria meningitidis Infections Drug Product Portfolios and Specifications &nbsp;13.2.3 Biological E Ltd Neisseria meningitidis Infections Drug Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.2.4 Biological E Ltd Main Business Overview &nbsp;13.2.5 Biological E Ltd Latest Developments &nbsp;13.3 China National Pharmaceutical Group Corp &nbsp;13.3.1 China National Pharmaceutical Group Corp Company Information &nbsp;13.3.2 China National Pharmaceutical Group Corp Neisseria meningitidis Infections Drug Product Portfolios and Specifications &nbsp;13.3.3 China National Pharmaceutical Group Corp Neisseria meningitidis Infections Drug Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.3.4 China National Pharmaceutical Group Corp Main Business Overview &nbsp;13.3.5 China National Pharmaceutical Group Corp Latest Developments &nbsp;13.4 GlaxoSmithKline Plc &nbsp;13.4.1 GlaxoSmithKline Plc Company Information &nbsp;13.4.2 GlaxoSmithKline Plc Neisseria meningitidis Infections Drug Product Portfolios and Specifications &nbsp;13.4.3 GlaxoSmithKline Plc Neisseria meningitidis Infections Drug Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.4.4 GlaxoSmithKline Plc Main Business Overview &nbsp;13.4.5 GlaxoSmithKline Plc Latest Developments &nbsp;13.5 Griffith University &nbsp;13.5.1 Griffith University Company Information &nbsp;13.5.2 Griffith University Neisseria meningitidis Infections Drug Product Portfolios and Specifications &nbsp;13.5.3 Griffith University Neisseria meningitidis Infections Drug Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.5.4 Griffith University Main Business Overview &nbsp;13.5.5 Griffith University Latest Developments &nbsp;13.6 ImmunoBiology Ltd &nbsp;13.6.1 ImmunoBiology Ltd Company Information &nbsp;13.6.2 ImmunoBiology Ltd Neisseria meningitidis Infections Drug Product Portfolios and Specifications &nbsp;13.6.3 ImmunoBiology Ltd Neisseria meningitidis Infections Drug Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.6.4 ImmunoBiology Ltd Main Business Overview &nbsp;13.6.5 ImmunoBiology Ltd Latest Developments &nbsp;13.7 JN-International Medical Corp &nbsp;13.7.1 JN-International Medical Corp Company Information &nbsp;13.7.2 JN-International Medical Corp Neisseria meningitidis Infections Drug Product Portfolios and Specifications &nbsp;13.7.3 JN-International Medical Corp Neisseria meningitidis Infections Drug Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.7.4 JN-International Medical Corp Main Business Overview &nbsp;13.7.5 JN-International Medical Corp Latest Developments &nbsp;13.8 MGB Biopharma Ltd &nbsp;13.8.1 MGB Biopharma Ltd Company Information &nbsp;13.8.2 MGB Biopharma Ltd Neisseria meningitidis Infections Drug Product Portfolios and Specifications &nbsp;13.8.3 MGB Biopharma Ltd Neisseria meningitidis Infections Drug Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.8.4 MGB Biopharma Ltd Main Business Overview &nbsp;13.8.5 MGB Biopharma Ltd Latest Developments &nbsp;13.9 Panacea Biotec Ltd &nbsp;13.9.1 Panacea Biotec Ltd Company Information &nbsp;13.9.2 Panacea Biotec Ltd Neisseria meningitidis Infections Drug Product Portfolios and Specifications &nbsp;13.9.3 Panacea Biotec Ltd Neisseria meningitidis Infections Drug Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.9.4 Panacea Biotec Ltd Main Business Overview &nbsp;13.9.5 Panacea Biotec Ltd Latest Developments &nbsp;13.10 Pfizer Inc &nbsp;13.10.1 Pfizer Inc Company Information &nbsp;13.10.2 Pfizer Inc Neisseria meningitidis Infections Drug Product Portfolios and Specifications &nbsp;13.10.3 Pfizer Inc Neisseria meningitidis Infections Drug Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.10.4 Pfizer Inc Main Business Overview &nbsp;13.10.5 Pfizer Inc Latest Developments &nbsp;13.11 Sanofi Pasteur SA &nbsp;13.11.1 Sanofi Pasteur SA Company Information &nbsp;13.11.2 Sanofi Pasteur SA Neisseria meningitidis Infections Drug Product Portfolios and Specifications &nbsp;13.11.3 Sanofi Pasteur SA Neisseria meningitidis Infections Drug Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.11.4 Sanofi Pasteur SA Main Business Overview &nbsp;13.11.5 Sanofi Pasteur SA Latest Developments &nbsp;13.12 Serum Institute of India Ltd &nbsp;13.12.1 Serum Institute of India Ltd Company Information &nbsp;13.12.2 Serum Institute of India Ltd Neisseria meningitidis Infections Drug Product Portfolios and Specifications &nbsp;13.12.3 Serum Institute of India Ltd Neisseria meningitidis Infections Drug Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.12.4 Serum Institute of India Ltd Main Business Overview &nbsp;13.12.5 Serum Institute of India Ltd Latest Developments &nbsp;13.13 Wellstat Vaccines LLC &nbsp;13.13.1 Wellstat Vaccines LLC Company Information &nbsp;13.13.2 Wellstat Vaccines LLC Neisseria meningitidis Infections Drug Product Portfolios and Specifications &nbsp;13.13.3 Wellstat Vaccines LLC Neisseria meningitidis Infections Drug Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.13.4 Wellstat Vaccines LLC Main Business Overview &nbsp;13.13.5 Wellstat Vaccines LLC Latest Developments 14 Research Findings and Conclusion

Report	Global Neisseria meningitidis Infections Drug Market Growth 2025-2031
Selected License	Multi ID: LPI23591

Buyer Information

Order Summary